Moderna
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Moderna and other ETFs, options, and stocks.About MRNA
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.
MRNA Key Statistics
MRNA News
Moderna (NASDAQ: MRNA) was a fine stock to heal an ailing portfolio on the second-to-last trading day of the week. The company, which developed and sells the Sp...
Pharmaceutical stocks Novo Nordisk (NVO) and Moderna (MRNA) are trending in opposite directions following their earnings reports. Despite topping Wall Street's...
Moderna Reports Smaller Than Expected Q1 Loss, Prepares For RSV Vaccine And Spikevax 2024-2025 Formula, Stock Soars Thursday, Moderna Inc (NASDAQ:MRNA) reporte...
Analyst ratings
48%
of 25 ratingsMore MRNA News
Merck Reports Progress On The Cancer Front As It Prepares For Keytruda Patent Expiration After topping expectations with first quarter revenue and adjusted ear...
With its Q1 2024 financials on Thursday, Moderna (NASDAQ:MRNA) highlighted its upcoming RSV vaccine, noting that the company expects U.S. regulators to recommen...
J.P. Morgan has lowered its rating of Metagenomi (NASDAQ:MGX) to neutral, citing the recent termination of its partnership with Moderna (MRNA). The investment...
Moderna (MRNA) stock broke out for the first time in over a year on May 2 after the biotech company notched a big quarterly beat on the back of its Covid vaccin...
Shares of pharmaceutical company Moderna (MRNA) are on the rise despite first quarter losses. Moderna CEO Stéphane Bancel tells Yahoo Finance Senior Reporter A...
Moderna (NASDAQ:MRNA) announced mixed results in the first quarter. The company swung to a loss of $3.07 in the first quarter, compared to earnings of $0.19 per...
Revenue: Reported $167 million, a significant decrease from $1.9 billion in the same quarter last year, exceeding the estimated $97.5 million. Net Loss: Record...
